drugset / Trial / NCT02718430

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

NCT02718430

Phase 1 Completed 6 enrolled Vaximm GmbH
NaSingle-groupOpen-labelTreatment

Summary

Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01

Timeline

Start
2016-02
Primary completion
2018-03
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Subject VXM01 Vaccine 1e+07 unknown Oral
Subject VXM01 Vaccine 1e+08 unknown Oral

Indications